[EN] CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF<br/>[FR] INHIBITEURS DE CAFÉINE DE MTHFD2 ET LEURS UTILISATIONS
申请人:RAZE THERAPEUTICS INC
公开号:WO2017106352A1
公开(公告)日:2017-06-22
The present invention provides compounds, compositions thereof, and methods of using the same.
本发明提供了化合物、其组合物以及使用方法。
[EN] PYRIMIDINE PDE10 INHIBITORS<br/>[FR] INHIBITEURS PYRIMIDINES DE PDE10
申请人:MERCK SHARP & DOHME
公开号:WO2013028590A1
公开(公告)日:2013-02-28
The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
ARYLOXMETHYL CYCLOPROPANE DERIVATIVES AS PDE10 INHIBITORS
申请人:Breslin Michael J.
公开号:US20140336195A1
公开(公告)日:2014-11-13
The present invention is directed to aryloxymethyl cyclopropane derivatives which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.